Copyright
©The Author(s) 2024.
World J Gastroenterol. Mar 21, 2024; 30(11): 1533-1544
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1533
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1533
Table 5 Comparison of 1-, 2-, and 3-year survival rates between the two groups
| Group | 1-yr survival rate | 2-yr survival rate | 3-yr survival rate | |||
| Number of cases | Survival rate (%) | Number of cases | Survival rate (%) | Number of cases | Survival rate (%) | |
| Research group (n = 50) | 47 | 94.00 | 42 | 84.00 | 36 | 72.00 |
| Control group (n = 50) | 40 | 80.00 | 32 | 64.00 | 20 | 40.00 |
| Log-χ2 value | 4.465 | 5.337 | 9.223 | |||
| P value | 0.035 | 0.021 | 0.002 | |||
- Citation: Yang LM, Wang HJ, Li SL, Gan GH, Deng WW, Chang YS, Zhang LF. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors. World J Gastroenterol 2024; 30(11): 1533-1544
- URL: https://www.wjgnet.com/1007-9327/full/v30/i11/1533.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i11.1533